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Background:
Results:
Conclusion:
Significance:

Mitochondrial proteins are controlled by glutaredoxin-2 (Grx2)-mediated deglutathionylation reactions.
Grx2 deficiency compromises cardiac mitochondrial functions leading to hypertrophy and fibrosis in male mice. This is
associated with deregulated glutathionylation reactions and mitochondrial dysfunction.
Through deglutathionylation, Grx2 controls mitochondrial oxidative phosphorylation in cardiac muscle.
Deregulated glutathionylation in heart can have pathological consequences.

Abstract: Glutaredoxin-2 (Grx2) modulates the activity of several
mitochondrial proteins in cardiac tissue by catalyzing deglutathionylation reactions. However, it remains uncertain whether Grx2 is
required to control mitochondrial ATP output in heart. Here, we
report that Grx2 plays a vital role modulating mitochondrial energetics and heart physiology by mediating the deglutathionylation
of mitochondrial proteins. Deletion of Grx2 (Grx2−/−) decreased
ATP production by complex I-linked substrates to half that in
wild type (WT) mitochondria. Decreased respiration was associated with increased complex I glutathionylation diminishing its
activity. Tissue glucose uptake was concomitantly increased. Mitochondrial ATP output and complex I activity could be recovered
by restoring the redox environment to that favoring the deglutathionylated states of proteins. Grx2−/− hearts also developed left
ventricular hypertrophy and fibrosis, and mice became hypertensive. Mitochondrial energetics from Grx2 heterozygotes (Grx2+/−)
were also dysfunctional, and hearts were hypertrophic. Intriguingly, Grx2+/− mice were far less hypertensive than Grx2−/− mice.
Thus, Grx2 plays a vital role in modulating mitochondrial metabolism in cardiac muscle, and Grx2 deficiency leads to pathology.
As mitochondrial ATP production was restored by the addition of
reductants, these findings may be relevant to novel redox-related
therapies in cardiac disease.
Keywords: Bioenergetics, Cardiac Hypertrophy, Cardiac Metabolism, Glutathionylation, Mitochondria, Redox, Glutaredoxin-2,
Glutathione, Oxidative Phosphorylation
Abbreviations: ROS — reactive oxygen species, Grx — glutaredoxin, OXPHOS — oxidative phosphorylation, RCR — respiratory control ratio, PSSG — protein glutathione disulfide, MnSOD — manganese superoxide dismutase, FCCP — carbonyl
cyanide p-trifluoromethoxyphenylhydrazone, ANOVA — analysis of variance, PET — positron emission tomography, β-MetOH
— β-mercaptoethanol

Introduction
Glutathionylation reactions have emerged as key posttranslational modifications required to control protein function in response to changes in redox (1). These modifications
involve the formation of a disulfide bridge between glutathione (GSH) and an available protein cysteine thiol. Reactions can either proceed nonenzymatically or enzymatically, depending on cell conditions (2). For instance, the
former occurs mostly during oxidative stress when 2GSH/
GSSG is ~1, and levels of reactive oxygen species (ROS)2 are
high. Nonenzymatic glutathionylation reactions are nonspecific and can lead to the hyper-glutathionylation of proteins, altering their activity (3–5). Enzymatic glutathionylation reactions, however, are tightly controlled and highly
specific post-translational modifications that occur normally
in response to fluctuations in local redox environments (6–
8). The glutaredoxin (Grx) proteins are currently thought to
be the chief enzymes that catalyze these reactions (9). Specifically the Grx proteins catalyze the deglutathionylation of
protein glutathione disulfide (PSSG) mixtures. In the cytosol, Grx1 is required to catalyze the deglutathionylation of
target proteins (10). Grx1 catalyzes the deglutathionylation
of protein targets in two steps as follows: 1) N-terminal cysteine on Grx1 deglutathionylates PSSG via a thiol disulfide
exchange reaction yielding the deglutathionylated protein
(PSH) and a Grx1-glutathionylated protein (SSG) intermediate; 2) Grx1-SSG binds GSH, and the glutathionyl moiety
is removed regenerating Grx1 and producing GSSG (11). Although the mechanistic details of the catalytic reaction still
require clarification (12), several models for the characteris-
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tic nucleophilic displacement ping-pong mechanism of Grx1
have been proposed and include a glutathione scaffold, glutathione activator, and an oxidative half-reaction (12). However, emerging evidence has also suggested that the Grx enzymes can also catalyze protein glutathionylation (13). This
can be mediated via the stabilization of a glutathione thiyl
radical that is then subsequently transferred to an available
protein thiol (13).
Mitochondrial processes are particularly susceptible to
regulation by glutathionylation. This is due to the unique
physical properties of the matrix environment. The slight
alkalinity of the matrix ionizes protein thiols increasing reactivity toward glutathione (14). Mitochondria also contain
high amounts of protein thiols (60–90 mm), reduced glutathione (GSH; ~5 mm), and are a major source of ROS, factors that render protein glutathionylation reactions more
favorable (14, 15). Mitochondrial redox environment fluctuations also occur during fuel oxidation, electron transfer,
and the formation of ROS. The thiol oxidoreductase glutaredoxin-2 (Grx2), which has ~34% homology to Grx1, was recently identified as the enzyme required to catalyze deglutathionylation reactions in mitochondria (16–19). The catalytic
cycle of Grx2 is also quite similar to Grx1 except that the
Grx2-SSG intermediate can be reduced by NADPH and thioredoxin reductase (20). It is also important to point out that
unlike Grx1, Grx2 complexes iron (Fe), which is required to
modulate its activity (21) (Grx2 regulation by coordination
of 2Fe-2S cluster was recently reviewed in detail in Refs. 22,
23). Intriguingly, Grx2 has been shown to catalyze both the
deglutathionylation and glutathionylation of target proteins
in mitochondria. The reversible nature of Grx2 is associated
with its sensitivity to changes in 2GSH/GSSG as follows: a
high 2GSH/GSSG promotes protein deglutathionylation and
a low 2GSH/GSSG activates Grx2 glutathionylase activity
(24, 25). The main target for Grx2 in mitochondria is complex
I (24). Increases and decreases in 2GSH/GSSG prompt Grx2mediated deglutathionylation and glutathionylation of complex I, which then alters its activity and superoxide production (24). Complex I has also been shown to be a Grx2 target
in lens epithelia and liver mitochondria (26–28). UCP3 has
also been shown to be targeted by Grx2 in skeletal muscle
(28). 2-Oxoglutarate dehydrogenase may also be targeted by
Grx2 because it can be deglutathionylated in vitro by exogenously added Grx1 (29).
The heart muscle turns over ~30 kg of ATP daily (30).
Clearly, mitochondrial ATP production is central to heart
function. A variety of control mechanisms converge on mitochondria to adjust ATP output. Changes in redox due to
temporal differences in mitochondrial metabolism (ROS production, NAD(P)H levels, and GSH and GSSG levels) can
feedback to modulate oxidative phosphorylation. A decrease
in 2GSH/GSSG could prompt glutathionylation of cardiac
mitochondrial proteins, although a reductive glutathione ratio has the opposite effect (24, 31). A number of glutathionylation targets in cardiac mitochondria have been identified,
including complex I subunit NDUSF1, complex II subunit
succinate dehydrogenase B, 2-oxoglutarate dehydrogenase,
and ATP synthase α subunit (25, 29, 32, 33). These proteins
fulfill important energetic roles in cardiac mitochondria, including energy substrate metabolism and oxidative phosphorylation. Alterations in the control of mitochondrial glutathionylation can have profound physiological effects. Grx2
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overexpression prevents doxorubicin-induced cardiac injury, and this is associated with recovery of mitochondrial
respiration (34). Irregularities in the glutathionylation of the
ATP synthase α subunit are associated with cardiac dysfunction (33). In addition, glutathionylation of complex I compromises aerobic metabolism in the heart, contributing to the
development of cardiac dysfunction (31). Ischemic reperfusion injury also alters the glutathionylation state of complex
II (32). Thus, the disruption of controlled protein glutathionylation reactions can compromise ATP output by cardiac
mitochondria, potentially leading to disease.
Despite the number of glutathionylation targets in cardiac
mitochondria, it still remains unknown if reversible glutathionylation can regulate oxidative phosphorylation (OXPHOS;
ATP output). It is also unclear if deregulation of protein deglutathionylation reactions (e.g. loss of Grx2 deglutathionylase
activity) in mitochondria can contribute to the development
of cardiac dysfunction. In this study, we examine the importance of Grx2 function in cardiac physiology and metabolism.
We used germ line Grx2 whole body knock-out (Grx2−/−,
Grx2-deficient) mice, which we have recently characterized
(28). In our previous study, we found that Grx2 deficiency did
not induce any major defects (linear growth, food intake, and
liver physiology), but we did note that hearts weighed significantly more (28). In this study, we examined the impact
of Grx2 deficiency on cardiac metabolism and function. We
found that OXPHOS was substantially decreased in cardiac
mitochondria from Grx2-deficient mice. The decrease in OXPHOS was due to the glutathionylation of complex I resulting
in decreased activity. These biochemical effects were reversed
with dithiothreitol (DTT), a reductant known to prompt protein deglutathionylation (35, 36), thereby favoring deglutathionylation. The biochemical changes in OXPHOS were associated with development of cardiac abnormalities, including
left ventricular hypertrophy, fibrosis, and a metabolic shift toward increased glucose uptake. We conclude that Grx2-mediated reversible glutathionylation is critical in modulating mitochondrial ATP output in cardiac muscle, and disruption of
this process is pathological.
Experimental Procedures
Animals. Studies were conducted on male C57BL/6 wild
type (WT) and Grx2 whole body knock-out (Grx2−/−) mice
aged 9–12 weeks that were backcrossed for over 10 generations into the C57BL/6 strain. Mice were fed ad libitum a standard diet (44.2% carbohydrate, 6.2% fat, 18.6% crude protein;
diet T.2018, Harlan, Indianapolis, IN). All experiments were
performed according to the principles and guidelines of the
Canadian Council of Animal Care, and the study was approved by the Animal Care Committee of the University of
Ottawa. Mice were genotyped for Grx2 prior to experimentation. Body and heart weights along with femur lengths were
measured. Serum hemoglobin levels were measured using a
kit purchased from Sigma, and assays were conducted as described by the manufacturer. For time profile experiments,
mice were aged either 6 or 10 weeks.
Echocardiography. For M-mode and pulsed-wave Doppler echocardiography, mice were anesthetized (2.0% isoflurane, 80 ml/min 100% O2); anterior chests were shaved, and
two-dimensional guided M-mode and pulsed-wave Doppler
echocardiography were performed using a VEVO 2100 sys-
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tem (Visual Sonics, Amsterdam) with a 30-MHz linear array transducer. Images and videos were analyzed using the
VEVO 2100 analysis software.
MicroPET Imaging. Small animal PET FDG imaging
was conducted with the InveonTM DPET small animal scanner (Siemens, Knoxville, TN). Mice were scanned under anesthesia (2–2.5% isoflurane, 2–2.5 ml/min oxygen) in a fed
state. A 60-min list-mode acquisition was started together
with a 10–20-s tail vein injection of FDG (25.9 ± 6.94 MBq in
150 μl). List data were sorted into 26 dynamic frames (12 ×
10, 3 × 60, and 11 × 300s) and reconstructed using OSEM3D
with 10 iterations, 16 subsets, zoom of 2.5 with a 128 × 128
matrix, resulting in a 0.35-mm transaxial pixel size. Images
were corrected for radioactive decay, random coincidences,
and dead-time losses using the vendor software (IAW version 1.5). Blood glucose was measured prior to FDG injection
with Advantage blood glucose strips (AccuChek, Roche Diagnostics). Myocardial time activity curves were compared
using standard uptake values calculated by dividing the activity concentration in the region of interest (Bq/ml) by the
activity concentration per body weight injected into the animal (Bq/g) (Siemens IRW software). Patlak kinetic analysis
of reconstructed images was performed on the myocardium
at 10–40 min as described previously with FlowQuant semiautomated software (63). Regional rate of myocardial glucose uptake (rMGU) was determined for each animal using
the Equation 1,
rMGU = Ki × BG/LC(mmol/min/g)

(1)

where Ki is the Patlak uptake rate constant; BG is the blood
glucose concentration, and LC is the lumped constant equal
to 0.67, which accounts for differences in the uptake and
phosphorylation of FDG versus glucose.
Fibrosis Determinations. Hearts were placed in 10%
formalin for 48 h and then in 70% ethanol prior to paraffin embedding. Transverse sections were taken at the vertical midpoint of the heart (4 μm each), and deparaffinized
sections were stained with Sirius Red, which stains fibrillar types 1 and 3 collagen. Analysis of the extent of fibrosis was determined using Zen software (Carl Zeiss Microscopy) whereby thresholds were set for collagen-stained
areas, and identified areas were expressed as a percentage
of the total tissue area.
Blood Pressure. Systolic blood pressure was determined
using a BP-2000 Blood Pressure Analysis SystemTM (Visitech
Systems; Apex, NC). This is a noninvasive computerized tailcuff system. Mice (age of 10 weeks) were placed on the BP200 platform (pre-warmed to 30 °C), and tails were passed
through the tail cuffs. Mice were acclimated to the system
daily for 5 days. After acclimation, blood pressure measurements were conducted between 9:00 and 11:00 a.m. daily for
5 days. Each day, mice were further acclimatized for 10 min
prior to the 20-min measurement period.
Mitochondrial Ultrastructure. Electron microscopic imaging was performed on fixed and stained sections of the
left ventricle. For heart fixation, mice were fully anesthetized
using isofluorane (~5%, O2 at ~1 liter/min). The left ventricle near the apex was punctured with a 25-gauge needle,
and a small incision was made in right atrium for fluid efflux. Hearts were then perfused slowly with heparinized saline until the efflux was clear and then perfused with fixative

et al. in

Journal

of

Biological Chemistry 289 (2014)

(2.5% glutaraldehyde + 2% formaldehyde in PBS). Hearts
were excised, placed in fixative, and stored at 4 °C. A Leica
Ultracut E ultramicrotome was used to section the tissue,
and sections were counterstained with lead citrate and uranyl acetate. Images were collected using JEOL 1230 transmission electron microscopy at 60 kV.
Mitochondrial Isolation. Mitochondria were isolated
as described previously (37). All steps were performed
on ice or at 4 °C. Hearts were excised and placed immediately in homogenizing buffer (HM: 220 mm mannitol, 70
mm sucrose, 5 mm HEPES, 1 mm EGTA, 10 mm pyruvate,
2 mm malate or 0.5 mm l-carnitine, 2 mm malate, pH 7.2).
On the day of experiments, HM was supplemented with
1% (w/v) defatted BSA + 2 units of subtilisin A. Tissue
was cut into small pieces and washed four times in HM.
Pieces were minced and then homogenized using the Potter-Elvehjem method. Homogenates were placed in centrifugation tubes and spun at 18,000 × g for 9 min. Pellets
were resuspended in fresh HM and centrifuged at 800 ×
g for 9 min. Supernatants were carefully transferred into
new centrifugation tubes and spun at 10,000 × g for 9 min.
The mitochondrial pellets were resuspended in a 100 μl of
HM devoid of BSA and subtilisin A. Protein content was
determined by a Bradford assay. Mitochondria were then
diluted according to protein equivalents (micrograms of
mitochondrial protein/ml) for various assays.
Mitochondrial Bioenergetics. The bioenergetics of isolated mitochondria were studied in a Seahorse XF24 extracellular flux analyzer (Seahorse Biosciences; North Billerica,
MA) using a method adapted from Refs. 28, 37. Mitochondria were diluted to 200 μg/ml in BSA-free HM, and 50 μl
(~10 μg of mitochondria) was loaded into each Seahorse TC
plate well. Mitochondria were attached to the plate surface
by centrifugation at 2000 × g for 20 min at 4 °C, incubated for
10 min in reaction buffer (HM containing 10 mm KH2PO4,
5 mm MgCl2, 0.2% w/v defatted BSA, with/without 10 mm
DTT + 10 mm pyruvate, 2 mm malate or 0.1 mm palmitoylcarnitine, 0.1 mm palmitate-BSA complex, 2 mm malate),
and loaded into the XF24 Analyzer.
Bioenergetic parameters were measured as described
previously (28). Following measurement of state 2 respiration (presence of substrate only), mitochondria were sequentially treated with ADP (0.1 mm), oligomycin (2.5 μg/
ml), FCCP (8 μm), and antimycin A (4 μm) to test state 3
(phosphorylating respiration), state 4O (proton leak-dependent respiration), maximal respiration (uncoupled), and
respiration independent of the respiratory chain, respectively. Respiratory control ratio (RCR) values were calculated by dividing the absolute rate of state 3 respiration by
state 4O respiration. ADP titration and cytochrome c titration experiments were performed as described previously
(28) to determine whether mitochondrial outer membranes
were intact. All values were corrected for background O2
consumption and any O2 consumption not associated with
the respiratory chain (antimycin A).
2GSH/GSSG. The potential of the 2GSH/GSSG pair
was determined as described previously (38). Isolated mitochondria were diluted to 0.5 mg/ml in ice-cold 0.5%
(v/v) perchloric acid solution and incubated on ice for 10
min. Samples were then centrifuged at 10,000 × g for 10
min at 4 °C to remove any precipitate. The supernatant
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was injected into an Agilent HPLC system equipped with
a Pursuit C18 column (150 × 4.6 mm, 5 μm; Agilent Technologies) operating at a flow rate of 1 ml/min. The mobile phase consisted of 1% trifluoroacetic acid diluted in
double distilled H2O and mixed with HPLC-grade methanol in a 90:10 ratio. Retention times for GSH and GSSG
were estimated by injecting standard solutions. Absolute amounts of GSH and GSSG were determined by integrating the area under each peak using Agilent ChemStation software. Values were interpolated from standard
curves to give nanomoles of GSH and GSSG. Values were
used to calculate millimolar amounts by assuming a mitochondrial volume of 0.75 μl (28, 39). Resulting values were
used to calculate 2GSH/GSSG and the Eh of the pair as
shown in Equation 2,
GSSG + 2e– + 2H– → 2GSH
Eh = –240 –

61.5 mV
[GSH]2
log
2
[GSSG]

(2)

at 37 °C.
Glutathionylated Proteome. Protein glutathionylation levels were determined as described previously
(28, 38). Freshly isolated mitochondria were treated with
25 mm N-ethylmaleimide to block unoccupied glutathionylation sites, and the suspension was diluted to 2 mg/
ml in Laemmli buffer. Samples were electrophoresed on
12% SDS gels under nonreducing conditions. Upon completion, proteins were electroblotted to nitrocellulose
membranes, blocked for nonspecific binding sites, and
probed with PSSG antiserum (1:500, Virogen). Note that
the antibody was diluted in 5% (w/v) nonfat skim milk
dissolved in TBS-T (Tris-buffered saline + 0.1% (v/v)
Tween 20) and incubated under constant agitation overnight at 4 °C. Membranes were then probed with antimouse HRP-conjugated secondary antibody diluted in 5%
(w/v) nonfat skim milk in TBS-T for 1 h at room temperature (1:3000, Santa Cruz Biotechnology). Between each
step, the membranes were washed two times for 5 min
with TBS-T. Samples prepared in Laemmli buffer containing 2% (v/v) β-mercaptoethanol (β-MetOH) served as the
control. β-Mercaptoethanol is a powerful reductant and is
thus very effective at removing glutathionyl moieties from
protein cysteine thiols. Thus, samples electrophoresed under reducing conditions ensure that the observed immunoreactivity of PSSG antiserum is due to the presence of
glutathionylated proteins. Immunoreactive bands were
detected using enhanced chemiluminescent substrate
for visualization (ECL kit, Thermo Scientific). Ponceau S
staining of membranes served as a loading control. The total amount of glutathionylated proteins was then quantified using ImageJ software.
Complex I Activity Assays. Mitochondria were treated
with 1% (v/v) digitonin and incubated on ice for 30 min.
Permeabilized mitochondria were then diluted to 0.5 mg/
ml in assay buffer (70 mm sucrose, 220 mm mannitol, 1
mm EGTA, 2 mm HEPES, 10 mm KH2PO4, 5 mm MgCl2,
0.2% w/v defatted BSA, pH 7.2) containing 2 mm KCN, 1
μm antimycin A, with or without 10 mm DTT. Reactions
were initiated by the addition of NADH (0.2 mm). The
rate of NADH consumption was calculated for the first 30
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s to 1 min of the reaction because this represents the time
for most rapid consumption of NADH. Reactions performed in the absence of mitochondria or NADH served
as controls. All values were corrected for background
NADH consumption.
The impact of 2GSH/GSSG and exogenous Grx1 on
complex I activity was tested as described previously
(24) with a few modifications. Digitonized mitochondria
were incubated at 37 °C in different amounts of reduced
and oxidized glutathione (GSH and GSSG, respectively)
to provide 2GSH/GSSG ratios of 100 and 1, respectively.
For mitochondrial preparations that were incubated with
a 2GSH/GSSG of ~1, incubations were also performed in
the absence or presence of 10 units of Grx1. Following a
5-min incubation, complex I activity was tested. The potential of the 2GSH/GSSG redox pair was calculated using Equation 2.
Mitochondrial ROS Emission. Mitochondrial ROS production kinetics were measured using dihydrodichlorofluorescein diacetate in a BioTek SynergyMX2 microplate reader
(Winooski, VT) using Gen5 software, as described previously (38). Mitochondria were diluted to 0.5 mg/ml in reaction buffer (70 mm sucrose, 220 mm mannitol, 1 mm EGTA,
2 mm HEPES, 10 mm KH2PO4, 5 mm MgCl2, 0.2% w/v defatted BSA, pH 7.2) containing dihydrodichlorofluorescein
diacetate (20 μm), 1 μg/ml oligomycin, with or without 10
mm DTT. Reactions were initiated by the addition of pyruvate (10 mm) and malate (2 mm). Reactions devoid of mitochondria served as the control. Values were corrected for
background fluorescence.
Metabolite Analysis. Mitochondria were diluted to 0.5
mg/ml in perchloric acid solution and clarified as described
above. Supernatants were then injected into an Agilent
HPLC system equipped with a C18 reverse phase hydrophilic
HPLC column (Synergy Hydro-RP, 4 μm, 250 × 4.6 mm; Phenomenex) and operated at a flow rate of 0.7 ml/min. The
mobile phase consisted of 20 mm KH2PO4 dissolved in double distilled H2O, pH 2.9. TCA cycle intermediates and ATP
were detected using an Agilent variable wavelength detector
set to 210 and 254 nm. Retention times were confirmed by injecting standard solutions. Levels of metabolites were quantified using Agilent ChemStation software.
Oxidative Damage. 4-Hydroxy-2-nonenal-histidine covalent adducts were measured using the OxiSelect ELISA
kit provided by CellBio Labs (CellBio Labs, San Diego). Assays were conducted according to the manufacturer’s instructions. 8-Hydroxy-2′-deoxyguanosine levels were measured by HPLC. Mitochondria were diluted to 0.5 mg/ml
in perchloric solution and incubated on ice as described
above. Following removal of precipitate, the clarified supernatant was injected into an Agilent HPLC system equipped
with a C18 reverse phase hydrophilic HPLC column (Synergy Hydro-RP, 4 μm, 250 × 4.6 mm; Phenomenex). Run
conditions were the same as described above. 8-Hydroxy2′-deoxyguanosine was detected using an Agilent variable wavelength detector set to 254 nm. Retention times
were confirmed by injecting standard solutions. We also injected 2′-deoxyguanosine standard solutions to ensure no
overlap with the retention and detection of 8-hydroxy-2′deoxyguanosine. Levels of metabolites were quantified using Agilent ChemStation software.
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Cytochrome c + c1 Concentration. Mitochondria were diluted to 1 mg/ml in BSA-free HM containing either excess
sodium dithionite (reducing) or ferricyanide (oxidizing), as
described previously (40, 41). Concentrations were determined by reading the maximum absorbance of mitochondria
at 550 nm. The difference in absorbance under reducing and
oxidizing conditions was then calculated and normalized
to isosbestic points measured at 535 nm. The concentration
of cytochrome c + c1 was determined according to the BeerLambert law, as described previously (42), with a molar extinction coefficient of 18,500 m−1·cm−1.
Immunoblots. Mitochondria were diluted to 2 mg/ml,
and protein was electrophoresed and electroblotted as described above. Ventricular heart tissue was mechanically
homogenized in homogenization buffer (50 mm Tris, pH
7.5, 1 mm EDTA disodium salt, 1 mm EGTA, 50 mm NaF,
5 mm sodium glycerophosphate, 10% v/v glycerol, 1% v/v
Triton X-100, 1 mm DTT, 1 mm PMSF), and protein content was determined by a BCA assay. Samples were electrophoresed on 15% isocratic, 12% isocratic, and 10% isocratic
SDS gels to afford proper immunodetection of Grx2, thioredoxin-2 (Trx2), uncoupling protein 3 (UCP3), and manganese superoxide dismutase (MnSOD). In addition, for MnSOD determinations only 15 μg of protein was loaded into
each well, whereas Trx2 and Grx2/UCP3 determinations
required 45 and 60 μg of protein, respectively, for proper
detection. Membranes were blocked and probed for 24 h at
4 °C with primary antibodies directed against Grx2 (1:500,
Abcam), Trx2 (1:1000, Abcam), UCP3 (1:1000, Abcam), and
MnSOD (1:3000, Santa Cruz Biotechnology). Membranes
were then incubated for 1 h at room temperature in the requisite secondary HRP-conjugated antibody. Succinate dehydrogenase A or α-tubulin served as the loading control
(1:2000, Santa Cruz Biotechnology) and (1:5000, Sigma) respectively. Immunoreactive bands were visualized as described above.
Simultaneous detection of different respiratory complex subunits was performed with the MitoProfile OXPHOS antibody mixture (Abcam). The mixture consisted
of five different antibodies directed against a specific subunit associated with each complex (I to V) as follows:
NDUFB8, succinate dehydrogenase B, UQCRC2, MTCO1,
and ATP5A. In bovine heart mitochondria, the ratio of complexes I/II/III/IV/V is estimated to be 1.1:1.3:3:6.7:3.5 indicating that the respiratory complexes vary in abundance
(41). To afford proper detection and resolution of each complex subunit, we electrophoresed 10 μg of mitochondrial
protein for detection of UQCRC2, MTCO1, and ATP5A and
45 μg of mitochondrial protein for NDUFB8 and succinate
dehydrogenase B. Electrophoresis and protein amounts
along with antibody dilution were optimized prior to experimentation. After blocking, membranes were probed
overnight at 4 °C under constant agitation. OXPHOS antibody was diluted by 1:800 in TBS-T supplemented with
5% (w/v) defatted BSA and 0.02% (w/v) NaN3. After three
washes in TBS-T membranes were probed with anti-mouse
HRP conjugate. Immunoreactive bands were identified using molecular weight markers and quantified with ImageJ
software. Quantification values were adjusted for the final
amount of protein used for detection.
NDUSF1 Glutathionylation. NDUSF1 glutathionylation
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was tested by immunoblot. Samples were loaded in duplicate on gels to allow alignment of NDUSF1 immunoreactive bands with PSSG immunoreactive bands that appear at
the same molecular weight. Mitochondria were diluted to 2
mg/ml in Laemmli buffer. 30 μg of sample was electrophoresed in 12% isocratic SDS gels. Following transfer of proteins to nitrocellulose membranes, membranes were stained
with Ponceau S and then cut in half vertically to be probed
for NDUSF1 and PSSG. As NDUSF1 has a molecular mass
of ~75 kDa, blots were cut a second time horizontally below the 50-kDa marker to measure MnSOD, which served as
the loading control. All blots were incubated overnight under constant agitation at 4 °C. NDUSF1 was diluted to 1:2000
in TBS-T, 5% (w/v) defatted BSA, 0.02% (w/v) NaN3, and
PSSG and MnSOD were diluted as described above. Experiments were also performed on samples electrophoresed under reducing conditions to ensure that the immunoreactive
bands in the 75-kDa range were due to interaction of PSSG
antiserum with glutathionylated proteins.
Statistics. Statistical analysis was performed using
GraphPad Prism 6 (GraphPad Software, La Jolla, CA). Comparison of controls with treated groups was performed with
Student’s t test. For comparisons of multiple treatments in
the same group with a control, one-way ANOVA with a post
hoc Tukey’s test was used.
Results
Grx2 Deficiency Induces Left Ventricular Hypertrophy
and Moderate Fibrosis but Does Not Compromise Heart
Contractility. Hearts from Grx2-deficient mice aged 9–12
weeks weighed significantly more (Figure 1a). No changes
in serum hemoglobin were observed indicating Grx2−/− mice
are not anemic (Figure 1b). Increased heart weight was associated with an increase in cardiomyocyte size and moderate
left ventricular fibrosis in mice at 9 weeks of age; no left ventricular fibrosis was observed at 6 weeks (Figure 1c). Histological analyses indicated concentric hypertrophy; there was
no evidence of myocytolysis or myocyte disarray. Echocardiographic measurements revealed that the left ventricular
wall was significantly thicker in Grx2-deficient mice (Figure
1, d and e). Measurement of the size of the interventricular
septum, left ventricular internal dimension, and left ventricular wall in diastole and systole confirmed that the left ventricle in Grx2−/− mice is hypertrophied (Table 1). Thus, the
increased heart size is associated with hypertrophying of
the left ventricle and fibrosis. We then calculated fractional
shortening and ejection fractions, indices for diastolic and
systolic function, and measured blood flow through the mitral valve during diastole. No significant changes in fractional shortening or ejection volume were observed (Figure
1e). At 16 weeks of age, left ventricles were still hypertrophied (Table 2), and a small but significant increase in fractional shortening and ejection volume was observed (Figure 1f). Despite this small increase in fractional shortening,
overall cardiac function (contraction and relaxation) was
maintained.
We next examined heart glucose uptake in vivo using the
glucose radiotracer analog [18F]FDG and microPET. Analysis
of representative images showed stark visual differences in
glucose uptake in the heart of Grx2−/− mice compared with
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Figure 1. Grx2 deficiency induces cardiac hypertrophy and left
ventricular fibrosis in 10-week-old mice. a, heart weight. Values
were normalized to femur length (g/cm). n = 4, mean ± S.E., Student’s
t test. b, serum hemoglobin levels. n = 6, mean ± S.E. c, histological
analysis of cell size (H&E) and fibrosis (Sirius Red) in left ventricle. d,
echocardiographic images of left ventricle in M-mode of mice aged 10
weeks. Left ventricular wall parameters (Tables 1 and 2) calculate left
ventricular wall mass, percent fractional contraction, and ejection efficiency in mice aged 10 weeks (e) and 16 weeks (f). n = 7, mean ±
S.E., Student’s t test.

Table 1. Echocardiographic measurement of left ventricular size and function in diastole and systole in male mice 10 weeks of age. All
measurements are in millimeters and were performed on M-mode images acquired with conscious mice. n = 7, mean ± S.E., Student’s t test. IVS
is interventricular septum; LVID is left ventricular internal dimension; LVPW is left ventricular posterior wall; d is diastole; s is systole.
IVS, d
WT
Grx2 –/–
a. p < 0.05
b. p < 0.01

0.68 ± 0.03
0.83 ± 0.02 a

LVID, d
4.38 ± 0.18
4.92 ± 0.19 a

LVPW, d
0.65 ± 0.03
0.80 ± 0.03 b

IVS, s
1.09 ± 0.04
1.18 ± 0.02 a

LVID, s
3.12 ± 0.15
3.61 ± 0.17 a

LVPW, s
1.01 ± 0.03
1.14 ± 0.05 a
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Table 2. Echocardiographic measurement of left ventricular size and function in diastole and systole in male mice 16 weeks of age. All
measurements are in millimeters and were performed on M-mode images acquired with conscious mice. n = 4, mean ± S.E., Student’s t test. IVS
is interventricular septum; LVID is left ventricular internal dimension; LVPW is left ventricular posterior wall; d is diastole; s is systole.

WT
Grx2–/–

IVS, d

LVID, d

LVPW, d

IVS, s

LVID, s

LVPW, s

0.62 ± 0.02
0.78 ± 0.02 a

4.46 ± 0.10
4.09 ± 0.11 a

0.66 ± 0.04
0.82 ± 0.05 b

0.95 ± 0.03
1.08 ± 0.04 b

3.11 ± 0.10
2.87 ± 0.08 b

1.06 ± 0.06
1.24 ± 0.06 a

a. p < 0.01
b. p < 0.05

Figure 2. Glucose uptake is increased in the left ventricle of Grx2-efficient mice. a, [18F]FDG images collected from WT and Grx2−/− mice.
Static images were collected after 60 min of imaging. White arrow represents location of heart. Asterisk denotes location of bladder. b, three-dimensional polar map of glucose uptake in left ventricle. Maps were generated after 60 min of imaging. The rate of myocardial glucose uptake
(rMGU) by the left ventricle was then calculated. n = 4–5, mean ± S.E., Student’s t test. c, dynamic measurement of the rate of [18F]FDG uptake by
left ventricle and septum. n = 4–5, mean ± S.E., Student’s t test. * denotes p < 0.05.

WT mice (Figure 2a). Three-dimensional polar mapping of
the left ventricle revealed significantly higher [18F]FDG uptake in this region of heart in Grx2−/− mice (Figure 2a). The
rate of [18F]FDG uptake by the left ventricle and septum was
also higher in Grx2−/− mice (Figure 2c).
Impact of Grx2 Deficiency on Mitochondrial OXPHOS
Proteins and Redox Environment. Electron microscopic analysis of sections from the left ventricle revealed no alterations
in cristae structure (Figure 3a). However, sharp changes
in the relative amounts of the various complexes were observed (Figure 3b). Significant decreases in complex I accessory protein NDUSB8, complex II subunit succinate dehydrogenase B, and complex IV subunit MTCO1 were evident
in Grx2-deficient mitochondria. Intriguingly, Grx2 deficiency

significantly increased the amounts of complex III subunit
UQCRC2 and complex V subunit ATP5A (Figure 3b). Grx2
deficiency also significantly increased the concentration of
cytochrome c + c1 in mitochondria (Figure 3c).
We next measured the impact of Grx2 deficiency on the
redox potential of mitochondria and the total glutathionylated proteome. Grx2−/− cardiac mitochondria contained significantly more GSSG than WT mitochondria (Table 3). In
addition the total glutathione pool was significantly larger
in Grx2−/− cardiac mitochondria suggesting that loss of Grx2
induces glutathione biosynthesis in the cytosol (Table 3). Although Grx2−/− mitochondria also contained more GSH, no
significance was recorded in comparison with WT. In Grx2deficient mitochondria, 2GSH/GSSG was approximately a
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Figure 3. Grx2 deficiency alters content of respiratory complexes and redox environment. a, electron microscopic images of mitochondrial
cristae structure in left ventricle. Scale bar, 500 nm. n = 3. b, immunoblot analysis of respiratory complex subunits. Protein bands were identified
and quantified to determine respiratory complex subunit amounts. n = 3, mean ± S.E., Student’s t test. SDHB, succinate dehydrogenase B. c, absolute content of cytochromes c and c1 in cardiac mitochondria. The absolute amounts were calculated from the difference in absorbance values
when mitochondria were fully reduced (dithiothreitol) or fully oxidized (ferrocyanide). n = 4, mean ± S.E., Student’s t test. d, measurement of the
mitochondrial 2GSH/GSSG ratio. Absolute amounts of reduced glutathione (GSH) and glutathione disulfide (GSSG) in mitochondria were measured by HPLC and then used to calculate the 2GSH/GSSG. The Eh of the ratio was then calculated using the Nernst equation. n = 4, mean ±
S.E., Student’s t test. * denotes p < 0.05. e, immunodetection of PSSG in cardiac mitochondria. Electrophoresis was conducted under nonreducing
(left) and reducing (right; + 2% v/v βMetOH). Bands were quantified using ImageJ software. n = 4, mean ± S.E., Student’s t test.
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Table 3. Absolute GSH and GSSG levels in WT and Grx2−/− cardiac
mitochondria. All values reported as mm/liter. Calculations were performed as described under “Experimental Procedures.” n = 4, mean ±
S.E., Student’s t test.
			
GSH
GSSG
WT
Grx2–/–

2.39 ± 0.065
3.24 ± 0.39

0.081 ± 0.014
0.27 ± 0.037 a

Total glutathione
(GSH + GSSG)
2.47 ± 0.069
3.51 ± 0.41 b

a. p < 0.01
b. p < 0.05

Figure 4. Grx2 deficiency does not induce oxidative damage in
cardiac mitochondria. a, measurement of 4-hydroxy-2-nonenal (4HNE) histidine adduct levels in isolated mitochondria. n = 4, mean ±
S.E., Student’s t test. b, assessment of 8-hydroxy-2′-deoxyguanosine
(8-OH-2′-deoxyguanosine) levels in isolated mitochondria. n = 4, mean
± S.E., Student’s t test. c, immunoblot analysis of MnSOD, uncoupling
protein-3 (UCP3) protein levels, Grx2, and Trx2. Succinate dehydrogenase (SDH) or α-tubulin served as loading controls.

quarter of the WT ratio (Figure 3d). The lower 2GSH/GSSG
had a significant effect on the potential (Eh) of the redox
pair (Figure 3d). Previous reports have estimated that the Eh
value of the 2GSH/GSSG varies between −280 and −340 mV
(43). From our calculations, the Eh value in WT mitochondria
falls within this range. Grx2 deficiency increases the Eh value
of this pair creating a more oxidizing matrix environment.
Grx2 is required to catalyze reversible glutathionylation,
but changes in 2GSH/GSSG can also alter the glutathionylation state of proteins as well. Grx2 deficiency significantly
increased the total amount of glutathionylated protein in
cardiac mitochondria (Figure 3e). The specificity of the antiPSSG antibody was confirmed by performing electrophoresis under reducing conditions (+βMetOH). As shown in Fig-
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ure 3e, addition of βMetOH abolished anti-PSSG antibody
binding, except for a faint band at ~40 kDa.
The increase in the Eh value of 2GSH/GSSG prompted
us to determine whether Grx2 deficiency induced oxidative damage or changes in the levels of antioxidative defense and redox enzymes. No differences in the levels of
4-hydroxy-2-nonenal-histidine adducts or 8-hydroxy-2′deoxyguanosine, two end products of ROS damage, were
observed in Grx2-deficient heart mitochondria when compared with WT (Figure 4, a and b). Thioredoxin-2 (Trx2) is
required to reduce intra- or intermolecular disulfide bridges
that may form during oxidative stress. No changes in Trx2
protein levels were recorded (Figure 4c). Also, no changes in
the protein levels of MnSOD were observed (Figure 4c). Collectively, our results indicate that Grx2 deficiency changes
mitochondrial redox, increases the glutathionylated proteome, and alters the composition of the respiratory complexes. However, these changes occurred in the absence of
oxidative damage.
Grx2 Deficiency Causes Dysfunctional Oxidative Phosphorylation. We next measured the impact of Grx2 deficiency on cardiac mitochondrial energetics using a high
throughput multiwell technique (28). Mitochondrial di-oxygen consumption was measured sequentially under state
2 (substrate only), state 3 (substrate + ADP), oligomycin-induced state 4 (proton leak-dependent respiration), and following treatment with protonophore FCCP (Figure 5, a and
b). No significant differences in proton leak-dependent respiration (state 4) were observed (Figure 5a). No significant
change in UCP3 protein was observed (Figure 4c). Remarkable, however, was the significantly lower rate of ADP-stimulated (state 3) respiration (Figure 5a). Addition of DTT to
reaction mixtures restored state 3 respiration in Grx2-deficient cardiac mitochondria to WT levels (Figure 5b). Similarly, uncoupled respiration was significantly lower in mitochondria isolated from Grx2−/− (Figure 5a) but could be
recovered to WT levels by the inclusion of DTT (Figure 5b).
The observation that uncoupled respiration in Grx2−/− cardiac mitochondria was also significantly decreased indicates
that the decrease in OXPHOS is likely associated with a decrease in the activity of a respiratory complex or complexes
rather than a decrease in ATP synthase activity.
The decrease in state 3 respiration resulted in an RCR that
was less than a half of the WT RCR (Figure 5c). Inclusion of
DTT in reaction mixtures restored RCR values in Grx2−/−
cardiac mitochondria to WT levels (Figure 5c). RCR was also
significantly decreased (~50%) when palmitoylcarnitine was
the respiratory substrate, and this was readily recovered by
the addition of DTT (Figure 5c). The observed decrease in
OXPHOS was confirmed by measuring absolute amounts of
ATP in mitochondria respiring on pyruvate and malate (Figure 6). A significant decrease in ATP synthesis was observed
in Grx2-deficient mitochondria. This was matched by significant decreases in various TCA cycle metabolites (Figure 6).
ADP titration experiments revealed that Grx2 deficiency
induced a modest decrease in the affinity of ATP synthase
for ADP (Figure 5e). We also examined whether changes in
respiration were due to damage to the outer membrane (e.g.
during mitochondrial isolation and attachment to the surface
of Seahorse TC plates). As shown in Figure 5f, no changes in
respiration were recorded following treatment of mitochondria with increasing concentrations of cytochrome c after induction of state 3 respiration.
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Figure 5. Grx2 deficiency decreases complex I-supported oxidative phosphorylation, which can be restored with DTT. Measurement of
O2 consumption in isolated cardiac mitochondria under different bioenergetic states was conducted using the Seahorse XF24. a and b, states 3,
state 4, and FCCP-induced uncoupled respiration rates in the absence or presence of 10 mm dithiothreitol (DTT). Pyruvate and malate were used
as substrates. Seahorse traces detailing the experiment are included in a and b. c, calculated respiratory control ratios for a and b. n = 4, mean ±
S.E., Student’s t test. d, calculated respiratory control ratios for mitochondria respiring on palmitoylcarnitine. e, ADP titration assay; f, mitochondrial
quality test. n = 3, mean ± S.E. Cyt c, cytochrome c; Ant A, antimycin A.

Impact of Grx2−/− and Redox Environment on Complex
I Activity and Glutathionylation. The specific activity of
complex I was significantly lower in Grx2-deficient cardiac
mitochondria when compared with WT (Figure 7a). Incubation in 10 mm DTT restored the activity of complex I in
Grx2-deficient mitochondria to levels that were not significantly different from those in WT mitochondria. We also
measured ROS production in isolated mitochondria. Grx2deficient mitochondria respiring on complex I-linked sub-

strates pyruvate and malate generated more ROS under state
4O conditions than WT cardiac mitochondria (Figure 7b).
Performing the reactions in the presence of 10 mm DTT lowered ROS emission by Grx2-deficient cardiac mitochondria
to WT levels.
Complex I has previously been reported to be modulated by glutathionylation (24, 27, 28). Thus, we next tested
whether complex I activity can be recovered with exogenously added Grx1 or GSH. We also wanted to determine
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Figure 6. ATP and tricarboxylic acid intermediate levels in cardiac
mitochondria are altered by Grx2 deficiency. Levels of various TCA
cycle metabolites and ATP were measured by HPLC as described under “Experimental Procedures.” n = 4, mean ± S.E., Student’s t test.

whether complex I activity in mitochondria from WT mice
could be inhibited by adding excess GSSG. Addition of 10
mm GSH and 0.1 mm GSSG did not alter complex I activity in WT cardiac mitochondria (Figure 7c). However, adjustment of the 2GSH/GSSG to ~1 induced an ~50% decrease
in complex I activity in WT mitochondria relative to control
(Figure 7c). Addition of exogenous Grx1 restored the activity of complex I to control levels in mitochondria exposed to
a 2GSH/GSSG of ~1 (Figure 7c). We next performed similar
determinations on Grx2−/− mitochondria. As shown in Figure 7c, complex I activity was lower in Grx2−/− mitochondria. This activity increased ~2.1-fold when 10 mm GSH was
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added (Figure 7c). Adjustment of the 2GSH/GSSG to ~1 did
not decrease the activity of complex I any further, relative to
control. Addition of exogenous Grx1 induced an ~2.3-fold
increase in complex I activity relative to control even when
the 2GSH/GSSG was set to ~1 (Figure 7c). These results illustrate that Grx plays a central role in reversing the deactivation of complex I by glutathionylation. In addition, our
results indicate that redox potential plays an important role
in modulating complex I activity. For instance, if the redox
potential of 2GSH/GSSG is highly oxidizing, it can lead to
spontaneous deactivation of complex I by glutathionylation. The opposite is also true for a highly reducing 2GSH/
GSSG, which spontaneously recovers complex I activity by
deglutathionylation.
The above results indicate that glutathionylation reactions mediated by Grx2 regulate complex I activity. We also
observed that excess GSSG can inhibit complex I. In a previous report, it was found that complex I subunit NDUSF1
is glutathionylated by Grx2 (25). We next used comparative
electrophoresis and immunoblotting to indirectly determine
whether Grx2 deficiency alters the glutathionylation state of
NDUSF1. Immunoblotting for protein glutathione disulfide
adducts (PSSG) revealed protein bands at ~72–75 kDa that
matched the electrophoretic mobility of NDUSF1 (Figure 7d).
The PSSG bands at this molecular weight were quantified
and normalized to the intensity of NDUSF1 immunoreactive
bands. These results suggest that NDUSF1 was more glutathionylated in mitochondria from the Grx2-deficient heart
(Figure 7d). Intriguingly, NDUSF1 levels were ~10% higher
in WT mitochondria. Immunoreactivity toward PSSG antiserum was abolished when samples were electrophoresed
under reductive conditions (+βMetOH) confirming that the
protein band detected at ~72–75 kDa was a glutathionylated
protein (Figure 7d). These results suggest that NDUSF1 may
be the site for glutathionylation of complex I.
OXPHOS and Heart Physiology in Younger Grx2-deficient Mice. Our above results demonstrate that mitochondria
from hearts of Grx2-deficient male mice aged 9–12 weeks
have decreased OXPHOS efficiency, which can be reversed
by adding DTT. We next decided to test the impact of Grx2
deficiency on mitochondrial energetics and heart physiology in mice aged 6 weeks. To afford a comparison, we also
measured OXPHOS and heart weights in mice that were 10
weeks of age. In mice aged 10 weeks, hearts from Grx2-deficient mice weighed significantly more than WT hearts (Figure 8a). These physiological changes coincided with a decrease in OXPHOS. Incubation of Grx2-deficient cardiac
mitochondria in 10 mm DTT restored the efficiency of ATP
production (Figure 8a). These observations are consistent
with the results generated above. Intriguingly, hearts from
6-week-old WT and Grx2−/− mice weighed the same, and
there were no signs of hypertrophy in the Grx2−/− mice (Figure 8b). In addition, no differences in the efficiency of OXPHOS were observed between WT and Grx2-deficient cardiac mitochondria (Figure 8b).
Heart Physiology and OXPHOS in Grx2 Heterozygotes. We next tested whether mice heterozygous for Grx2
(Grx2+/−) also presented with abnormalities in OXPHOS.
Weights of hearts from Grx2+/− and Grx2−/− mice were similar and were heavier than hearts from WT mice (Figure 9a).
The amount of Grx2 protein in Grx2+/− mitochondria was
approximately half that in WT mitochondria (Figure 9b). We
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Figure 7. Complex I activity is
compromised but is recovered
by restoration of redox environment. Measurement of complex I activity (a) and mitochondrial ROS production (b) in the
absence or presence of 10 mm dithiothreitol (DTT). n = 4, mean ±
S.E., Student’s t test. c, complex I
activity can be recovered by restoration of redox environment or
the addition of exogenous glutaredoxin-1 (Grx). Mitochondria were
permeabilized and then incubated
for 5 min in various combinations
of reduced glutathione (GSH), oxidized glutathione (GSSG) in the
absence or presence of 10 units
Grx. Complex I activity was then
measured. The Eh values were
estimated according to the Nernst
equation (see Equation 1). n = 5,
mean ± S.E., 1-way ANOVA with
a post hoc Tukey’s test. * denotes
p < 0.05. d, estimation of the glutathionylation state of complex I
subunit NDUSF1 (~75 kDa) by immunoblot. Glutathionylation state
was preserved by treating mitochondria with 25 mm N-ethylmaleimide. To afford a proper electrophoretic estimation of NDUSF1
glutathionylation, NDUSF1 and
PSSG levels were detected on
the same gels. Samples were also
electrophoresed under reducing
conditions (+2% v/v βMetOH) as
a control for PSSG immunodetection. Bands were quantified using
ImageJ. n = 3, mean ± S.E., Student’s t test. Mice were age 9–12
weeks.

then tested the impact of Grx2+/− on OXPHOS efficiency. As
shown in Figure 9c, mitochondria from Grx2+/− mice had decreased RCRs, similar to values from Grx2−/− mice (Figure
9c). Treatment of mitochondria with 10 mm DTT recovered
RCRs in mitochondria from Grx2+/− and Grx2−/− mice (Figure 9c). Left ventricular hypertrophy is often induced by
hemodynamic stress. Thus, we assessed diastolic and sys-

tolic blood pressure to discern if hypertension and hemodynamic stress were evident. At 9 weeks of age, systolic blood
pressure in Grx2-deficient mice was the highest (Figure 9d).
Systolic pressure was also elevated in mice heterozygous
for Grx2 but not to the same magnitude as Grx2-deficient
mice. No differences in diastolic pressure were observed at
9 weeks of age (Figure 9d). Intriguingly, at 6 weeks the sys-
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Figure 8. Effect of age on OXPHOS
and heart weight. a and b, measurement of RCR in mitochondria isolated
from WT and Grx2−/− mice aged 10
and 6 weeks. RCR values were calculated by dividing absolute state 3 respiration rates by state 4O respiration
rates. Hearts were weighed prior to experimentation and normalized to femur
length (g/cm). n = 4, mean ± S.E., Student’s t test.

tolic blood pressure in Grx2 heterozygous mice was comparable with WT (Figure 9d). By contrast, systolic blood pressure in Grx2-deficient mice was still significantly elevated.
At 6 weeks of age, diastolic blood pressure was significantly
lower in Grx2-deficient mice and mice heterozygous for
Grx2 compared with WT mice (Figure 9d).
Discussion
Mitochondrial dysfunction contributes to the pathogenesis of a number of diseases, including neurological disorders, obesity, type 2 diabetes, and cardiovascular disorders.
Perturbations in mitochondrial function have also been as-

sociated with cardiac injury and heart failure (44). Studies
have established that defects in mitochondrial bioenergetics
are associated with development of heart disease. Dysfunctional mitochondria in cardiac tissue can lead to energy starvation, which is associated with defects in the conversion of
fuels into ATP (45). Recent work has shown that perturbations in post-translational modifications that regulate OXPHOS, like acetylation, can result in heart disease (44). In
particular, a recent study established that regulation of complex I by acetylation in cardiac tissue is essential for responding to chronic increases in workload (44). In this study, we
have established that Grx2 plays a central role in regulating
OXPHOS efficiency in cardiac mitochondria. The importance
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Figure 9. Grx2 heterozygotes. a, heart weight. Values were normalized to femur length (g/cm). b, Grx2
protein levels. c, calculated RCR for isolated cardiac mitochondria. Pyruvate and malate served as
the respiratory substrate. n
= 3, mean ± S.E., one-way
ANOVA with Tukey’s post
hoc test. d, measurement of
systolic and diastolic blood
pressure. n = 6, mean ±
S.E., one-way ANOVA with
a post hoc Tukey’s test, *
and ** denote p < 0.05 and
p < 0.01. Mice were aged
9–12 weeks.

of Grx2 in maintaining efficient mitochondrial respiration
in cardiac tissue stems from its capacity to deglutathionylate target proteins like complex I. Loss of Grx2 led to the hyper-glutathionylation of the mitochondrial proteome and decreased OXPHOS efficiency. Grx2 deficiency was associated
with cardiac hypertrophy and hypertension. Intriguingly,
Grx2 heterozygous mice also had cardiac hypertrophy and
a decrease in mitochondrial ATP production associated with
defective complex I activity. However, Grx2 heterozygotes
presented with a milder degree of hypertension suggesting
that perturbations in mitochondria can contribute to development of heart disease. To our knowledge, this is the first
study to show that controlled glutathionylation reactions
mediated by Grx2 are key for modulating cardiac mitochondrial energetics. In addition, we provide evidence that intrinsic factors, such as deregulation of redox signaling, can contribute to development of heart disease.
Complex I is a major site for respiratory chain control in
the heart (46). Indeed, complex I can serve as a major therapeutic target for prevention of cardiac ischemic-reperfusion injury (46). Thus, a need for a better understanding of
the mechanisms that control complex I activity in cardiac tissue is required. We confirmed that complex I is a major target for Grx2-mediated deglutathionylation and demonstrated
that complex I activity was decreased with Grx2 deficiency
and that this could be reversed with DTT, exogenous Grx1,

or GSH. Importantly, similar observations have been made in
previous studies where addition of DTT, exogenous Grx1, or
simply adding GSH to reactions reversed glutathionylation
and activated mitochondrial proteins like complex I or carnitine/acyl-carnitine carrier (25, 31, 47). We also provided evidence that NDUSF1 subunit of complex I may be the site for
glutathionylation of complex I. In addition, the band at ~72–
75 kDa was more glutathionylated mitochondria from Grx2deficient mice. β-MetOH abolished band reactivity at ~72–75
kDa confirming that NDUSF1 is glutathionylated. This observation is in line with previous studies that showed that
Cys531 and Cys704 on NDUSF1 are sites for glutathionylation
(25). In addition, recent work has shown that NDUSF1 is a target for S-nitrosylation and S-oxidation reactions (25, 46). We
also noted that NDUSF1 levels were ~11% higher in WT mitochondria indicating Grx2 deficiency can also affect the expression of mitochondrial proteins. It is important to point
out that other subunits for complex I, including Ndufv1 (~51
kDa), have been shown to be glutathionylated in perfused isolated mouse hearts (48). Another subunit with a mass of ~40
kDa have also been shown to be glutathionylated (31). This
coincides with the mass of the ND3 subunit of complex I that
harbors Cys39, which can be modified by S-oxidation reactions
(49). It has been reported that complex I transitions between
activated (A-form) and deactivated (D-form) states that regulate its activity (50). In the transition to the D-form, Cys39 on
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ND3 becomes accessible and thus amenable to S-oxidation.
Thus, ND3 subunit could serve as an important site for regulation of complex I activity by glutathionylation (51). Simultaneous immunoblotting for specific subunits for all respiratory complexes revealed that Grx2 deficiency decreased the
amount of complex I subunit NDUFB8. This subunit is an accessory protein that plays no catalytic role in complex I. However, NDUFB8 has been suggested to be required for supercomplex assembly in mitochondria (52). According to our
results, complex I activity is influenced by its “state of glutathionylation,” which is directly modulated by Grx2 and not
by the decrease in NDUFB8. Indeed, inclusion of DTT, restoration of 2GSH/GSSG, or addition of exogenous Grx1 fully
recovered complex I activity in Grx2-deficient mitochondria.
We also observed that high GSSG inhibited complex I activity in WT mitochondria, which is consistent with previous observations that if GSSG levels are high enough then glutathionylation of complex I can proceed via a simple thiol exchange
reaction (53, 54). Inclusion of exogenous Grx1 with GSSG prevented the deactivation of complex I by GSSG in WT mitochondria. It is important to consider though that inclusion of
GSSG at high concentrations may influence complex I activity
by altering the redox state of other redox couples. Addition of
GSSG can deplete NADPH pools and result in the oxidation
of thioredoxin-2. However, based on our results and work
published by others (24, 31), we can conclude that GSSG lowers complex I activity by glutathionylation and that this can be
reversed by either restoring the mitochondrial redox environment or in the presence of Grx2.
We also observed that Grx2 deficiency drastically altered the protein levels of all other measured respiratory
complex subunits and cytochrome c. We also observed that
the TCA cycle metabolite pool was diminished. The loss of
a functional TCA cycle and changes in the protein levels
of the respiratory complexes would inevitably also impact
OXPHOS capacity. Deletion of Grx2 resulted in the glutathionylation of a number of mitochondrial proteins. Thus,
Grx2 may have many mitochondrial protein targets, including TCA cycle enzymes. Indeed, previous reports have
shown that various TCA cycle enzymes can be glutathionylated (22, 55, 56) and that cardiac ATP synthase is deactivated by glutathionylation (57). In our study, we observed
that Grx2 deficiency induced a modest decrease in the sensitivity of ATP synthase toward ADP. However, it is also
important to point out that adenine nucleotide translocator is also a target for glutathionylation, which may affect
its capacity to exchange adenine nucleotides and would
affect ATP synthase activity (58). Previous reports have
shown that glutathionylation of the α subunit of ATP synthase diminishes ATP production (33, 35). Although our
results do indicate that ATP synthase could potentially be
affected by Grx2 deficiency, further analyses must be conducted to properly evaluate the sensitivity of ATP synthase
in Grx2−/− mitochondria toward ADP.
Our analyses also revealed defective cardiac mitochondrial energetics in Grx2-deficient mitochondria respiring on
either complex I-linked substrates or fatty acids, consistent
with a recent report that carnitine/acylcarnitine carrier is
inhibited by glutathionylation (47). Importantly, glutathionylation of carnitine/acylcarnitine carrier can be reversed
by addition of exogenous Grx1 or DTT in vitro (47). It is important to acknowledge that fatty acid oxidation in mito-
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chondria serves as the main source of ATP in cardiac tissue.
Indeed, this inability to use fatty acids or TCA cycle substrates was associated with increased glucose uptake and
reliance on glycolysis to produce ATP. Decreased OXPHOS
in cardiac mitochondria induces a shift toward glycolysis to
preserve ATP pools (59). Notably, we have demonstrated
that the addition of DTT to Grx2-deficient cardiac mitochondria restored OXPHOS, thus indicating that the primary cause of the observed defects in mitochondrial function were due to perturbed redox and glutathionylation
reactions.
Hearts from 9- to 12-week-old Grx2-deficient mice were
heavier and presented with left ventricular hypertrophy
and fibrosis. Grx2-deficient mice were also hypertensive
indicating that hemodynamic stress may be responsible
for the hypertrophying of the left ventricle. In Grx2+/−
mice, hearts were also hypertrophied, and ATP production was decreased to values half those of WT controls.
As in Grx2−/− mitochondria, OXPHOS could be fully recovered by the addition of DTT to reaction mixtures. Intriguingly though, systolic blood pressure in 6-week-old
Grx2+/− mice was not significantly different compared
with WT mice. At 9 weeks, increased blood pressure was
observed in Grx2+/− mice, but the levels were not as high
as in Grx2−/− mice. Left ventricular hypertrophy is often
associated with increased hemodynamic stress associated with hypertension (60). However, deregulated ATP
production by mitochondria has also been implicated in
left ventricular hypertrophy, which would indicate that
cardiac disease can be caused by intrinsic (cardiac mitochondrial dysfunction) and extrinsic stress (hemodynamic
stress) (61). Thus, the cardiac hypertrophy in mice heterozygous for Grx2 is likely more directly associated with deregulated mitochondrial glutathionylation and inefficient
ATP production, whereas in Grx2−/− mice left ventricular hypertrophy and fibrosis are due to a mixture of extrinsic and intrinsic stressors (hemodynamic stress and
inadequate mitochondrial ATP production). It is important to note that Grx2−/− did not induce oxidative damage, oxidative stress, or changes in mitochondrial ultrastructure. Although we cannot exclude the possibility that
the increased ROS production by mitochondria and decreased 2GSH/GSSG ratio may also contribute to the observed hypertrophy, it can be concluded that deregulated
mitochondrial glutathionylation reactions are responsible, in part, for the observed cardiac hypertrophy. It has
been previously reported that myocardial overexpression
of Grx2 maintains mitochondrial OXPHOS in mice treated
with doxorubicin, a chemotherapeutic that can induce cardiac dysfunction (34). Also, Brautigam et al. (62) observed
that silencing Grx2 in zebrafish does not induce oxidative
stress but does induce neuronal cell death due to changes
in redox and possibly protein glutathionylation.
This is the first study to investigate the relationship between Grx2-mediated regulation of mitochondrial bioenergetics and heart function. We demonstrated that Grx2 is a
key component of the regulatory machinery of cardiac mitochondria. Loss of Grx2 function leads to deregulated mitochondrial glutathionylation, changes in mitochondrial redox
state, and decreased mitochondrial ATP output. Our work
also revealed that OXPHOS can be recovered by restoring
the reductive nature of the mitochondrial redox environ-
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ment. Collectively our findings illustrate that redox signaling plays a vital role in regulating mitochondrial OXPHOS
in the heart and that disruption of glutathionylation reactions can lead to heart disease. The observation that glutathionylation status and mitochondrial function can be restored
with reducing agents also indicates that therapies could potentially be designed to restore the mitochondrial glutathiome and thereby curtail the progression of heart disease.
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